Ac-YVAD-CHO
Based on 1 Customer Validation
Ac-YVAD-CHO (L-709049) is a potent, reversible, specific tetrapeptide interleukin-lβ converting enzyme (ICE) inhibitor with mouse and human Ki values of 3.0 and 0.76 nM. Ac-YVAD-CHO is also a caspase-1 inhibitor. Ac-YVAD-CHO can suppress the production of mature IL-lβ.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 98.99%
- CAS. Nr.: 143313-51-3
- Formel: C23H32N4O8
- Molecular Weight:492.52
-
Speicherung:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Alle Caspase Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
|
IL-1β |
Caspase-1 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| PBMC | IC50 |
1.2 μM
Compound: 1
|
Inhibition of LPS-induced IL1-beta production in human PBMC by ELISA
Inhibition of LPS-induced IL1-beta production in human PBMC by ELISA
|
[PMID: 20656488] |
| THP-1 | IC50 |
2 μM
Compound: Ac-YVAD-CHO
|
Induction of IL-1 beta production in LPS-induced human THP-1 cells by ELISA
Induction of IL-1 beta production in LPS-induced human THP-1 cells by ELISA
|
[PMID: 21916432] |
| THP-1 | IC50 |
6.8 x 10-5 M
Compound: 1a
|
Amidolytic activity of THP.1 cell lysate against IL-1 beta converting enzyme using C1-Asp-AMC as a substrate
Amidolytic activity of THP.1 cell lysate against IL-1 beta converting enzyme using C1-Asp-AMC as a substrate
|
[PMID: 9873373] |
| THP-1 | IC50 |
0.00019 M
Compound: 1a
|
Amidolytic activity of THP.1 cell lysate against Caspase-3 using C3-Asp-AMC as a substrate
Amidolytic activity of THP.1 cell lysate against Caspase-3 using C3-Asp-AMC as a substrate
|
[PMID: 9873373] |
| THP-1 | IC50 |
0.19 mM
Compound: 1a
|
Amidolytic activity of THP.1 cell lysate against Caspase-3 using C3-Asp-AMC as a substrate
Amidolytic activity of THP.1 cell lysate against Caspase-3 using C3-Asp-AMC as a substrate
|
[PMID: 9873373] |
In Vitro
Ac-YVAD-CHO inhibits mouse and human IL-1β with IC50 values of 2.5 and 0.7 μM respectively[1].
Ac-YVAD-CHO (0.01-100 μM) reduces the elevations of IL-lβ in the plasma and peritoneal fluid treated with LPS[1].
Ac-YVAD-CHO (15.6 μM) reduces NO-induced thymocyte apoptosis[3].
Ac-YVAD-CHO (15.6 μM, 12 h) inhibits NO-induced PARP cleavage in SNAP-treated thymocytes[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:SNAP-treated thymocytes
-
Concentration:15.6 μM
-
Incubation Time:12 h
-
Result:Reduced PARP cleavage.
In Vivo
Ac-YVAD-CHO (2-8 μg, intrastriatal infusion) attenuates Quinolinic acid (QA)-induced apoptosis in rat striatum[2].
Ac-YVAD-CHO (10 and 50 mg/kg; i.p.; 1 hour) is cleared from the blood rapidly, and drops precipitously to approximately 1 and 0.2 μM at 30 and 60 minutes after injection[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:P. acnes-sensitized mice[1]
-
Dosage:50 mg/kg
-
Administration:I.p.;
-
Result:Suppressed IL-1β levels in blood.
-
Animal Model:Quinolinic acid-treated Rats[2]
-
Dosage:2-8 μg
-
Administration:Intrastriatal infusion.
-
Result:Attenuated Quinolinic acid (QA)-induced increases in p53 and apoptosis in rat striatum.
Inhibited QA-induced increases in caspase-1 activity and p53 protein levels, with no effect on QA-induced IκB-α degradation, NF-κB or AP-1 activation.
Chemical Information
-
CAS. Nr. 143313-51-3
-
Appearance Solid
-
Molecular Weight 492.52
-
Formel C23H32N4O8
-
Color White to off-white
-
Synonyms
L-709049
-
Sequence Shortening
Ac-YVAD-CHO
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Lösungsmittel & Löslichkeit
In Vitro:
H2O : ≥ 50 mg/mL (101.52 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Protokoll
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Reinheit & Dokumentation
-
Data Sheet (275 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Fletcher DS, et al. A synthetic inhibitor of interleukin-1 beta converting enzyme prevents endotoxin-induced interleukin-1 beta production in vitro and in vivo. J Interferon Cytokine Res. 1995;15(3):243-248. [Content Brief]
[2]. Cao Y, et al. Caspase-1 inhibitor Ac-YVAD-CHO attenuates quinolinic acid-induced increases in p53 and apoptosis in rat striatum. Acta Pharmacol Sin. 2005 Feb;26(2):150-4. [Content Brief]
[3]. Zhou X, et al. Nitric oxide induces thymocyte apoptosis via a caspase-1-dependent mechanism. J Immunol. 2000 Aug 1;165(3):1252-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 2.0304 mL | 10.1519 mL | 20.3037 mL | 50.7594 mL |
| 5 mM | 0.4061 mL | 2.0304 mL | 4.0607 mL | 10.1519 mL | |
| 10 mM | 0.2030 mL | 1.0152 mL | 2.0304 mL | 5.0759 mL | |
| 15 mM | 0.1354 mL | 0.6768 mL | 1.3536 mL | 3.3840 mL | |
| 20 mM | 0.1015 mL | 0.5076 mL | 1.0152 mL | 2.5380 mL | |
| 25 mM | 0.0812 mL | 0.4061 mL | 0.8121 mL | 2.0304 mL | |
| 30 mM | 0.0677 mL | 0.3384 mL | 0.6768 mL | 1.6920 mL | |
| 40 mM | 0.0508 mL | 0.2538 mL | 0.5076 mL | 1.2690 mL | |
| 50 mM | 0.0406 mL | 0.2030 mL | 0.4061 mL | 1.0152 mL | |
| 60 mM | 0.0338 mL | 0.1692 mL | 0.3384 mL | 0.8460 mL | |
| 80 mM | 0.0254 mL | 0.1269 mL | 0.2538 mL | 0.6345 mL | |
| 100 mM | 0.0203 mL | 0.1015 mL | 0.2030 mL | 0.5076 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.